National Cancer Institute to Grant Exclusive Patent License to Kite Pharma for Anti-CD70 Cancer Treatment

Summary

The National Institutes of Health is considering a license agreement with Kite Pharma, a biotech company based in Santa Monica, California, to develop and commercialize anti-CD70 chimeric antigen receptors for treating cancers that express the CD70 protein.